Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Chinese PLA General Hospital
National Institutes of Health Clinical Center (CC)
AvenCell Therapeutics, Inc.
University of Chicago
Allogene Therapeutics
Genmab
Genmab
Genmab
National Institutes of Health Clinical Center (CC)
Medical University of South Carolina
Ossium Health, Inc.
Lyell Immunopharma, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Essen Biotech
Dana-Farber Cancer Institute
AstraZeneca
University of Michigan Rogel Cancer Center
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
University of Washington
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Fondazione Italiana Linfomi - ETS
UNC Lineberger Comprehensive Cancer Center
Fred Hutchinson Cancer Center
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Gilead Sciences
St. Jude Children's Research Hospital
Chinese PLA General Hospital
Princess Maxima Center for Pediatric Oncology
Princess Maxima Center for Pediatric Oncology
Princess Maxima Center for Pediatric Oncology
Zhejiang Teruisi Pharmaceutical Inc.
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
M.D. Anderson Cancer Center
Juventas Cell Therapy Ltd.
National Institutes of Health Clinical Center (CC)
Chinese PLA General Hospital
Chinese PLA General Hospital
Artiva Biotherapeutics, Inc.
Indapta Therapeutics, INC.
Chinese PLA General Hospital
M.D. Anderson Cancer Center
Institute of Hematology & Blood Diseases Hospital, China
Memorial Sloan Kettering Cancer Center
OHSU Knight Cancer Institute
City of Hope Medical Center